Evidence map›Paper›PMID 30701582›Full record

ArticleBritish journal of clinical pharmacology2019

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.

R Cohen, L H Preta, V Joste, E Curis, O Huillard, A Jouinot, C Narjoz, A Thomas-Schoemann, A Bellesoeur, M Tiako Meyo and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.Drug metabolism and disposition: the biological fate of chemicals · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

R CohenDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.ORCID 0000-0001-9602-5162
L H PretaPharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
V JosteBiochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France.
E CurisLaboratory of biomathematics, plateau iB2, Pharmacy Faculty, University of Paris Descartes, Paris, France.
O HuillardDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
A JouinotDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
C NarjozBiochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France.
A Thomas-SchoemannUMR8638 CNRS, Paris Descartes University, Pharmacy Faculty, University of Paris Descartes, Paris, France.
A BellesoeurMultidisciplinary risk assessment and Drug Monitoring, Cochin Hospital, AP-HP, Paris.
M Tiako MeyoPharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
J QuilichiniPharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
D DesaulleLaboratory of biomathematics, EA 4064 Environmental epidemiology and impact of pollution on health, Pharmacy Faculty, University of Paris Descartes, Paris, France.
I NicolisLaboratory of biomathematics, EA 4064 Environmental epidemiology and impact of pollution on health, Pharmacy Faculty, University of Paris Descartes, Paris, France.
A CessotDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
M VidalPharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
F GoldwasserDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
J AlexandreDepartment of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
B BlanchetPharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
Délégation Paris 5 · FRUniversité Paris Cité · FRHôpital Cochin · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCytidine deaminase (CDA) activity in cancer patients' serum has been proposed as a predictive biomarker for efficacy and toxicity of nucleoside analogues. However, discrepant results about its predictive value have been reported due to the high interindividual variability in CDA activity. This study aimed at identifying determinants of this interindividual variability.

methodsFrom December 2014 to November 2015, 183 patients were prospectively included. Serum CDA activity, biological and clinical characteristics as well as five common single nucleotide polymorphisms (SNPs) in the CDA gene (c.-451C > T, c.-92A > G, c.-33_-31delC, c.79A > C, c.435 T > C) were analysed. Associations between clinical characteristics, pharmacogenetic variants and CDA activity were univariately tested. P < 0.1-candidate variables were analysed through a multivariate analysis. The association between CDA activity and toxicity was assessed for the 56 gemcitabine-treated patients. Intraindividual variability in CDA activity was explored in six pancreatic cancer patients treated with gemcitabine.

resultsMedian CDA activity was 3.97 U mg

conclusionsThese results suggest that neutrophil count and malnutrition should be considered for the interpretation of pretherapeutic CDA activity.

Indexed as

Biological Variation, PopulationAgedAntimetabolites, AntineoplasticBiomarkers, TumorCytidine DeaminaseDeoxycytidineDrug MonitoringFemaleGemcitabineHumansInflammationMaleMalnutritionMiddle AgedNeutrophilsNutritional StatusAntimetabolites, AntineoplasticBiomarkers, TumorCytidine DeaminaseDeoxycytidineGemcitabinecytidine deaminasegemcitabinegenotypeinterindividual variabilitynucleoside analogues

Identifiers

PMID30701582
PMCPMC6533495
OpenAlexW2908265756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.